Generex Biotechnology Chief Medical & Scientific Officer Dr. Jason Terrell, MD is Awarded the 2019 Shepperd Pathfinder Award from the John Ben Shepperd Public Leadership InstituteDr. Terrell is recognized for his Work in the Fight Against Cancer

MIRAMAR, Fla., Oct. 18, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT) is pleased and proud to announce that the company’s Chief Medical and Scientific Officer Dr. Jason Terrell, MD was recently awarded the Shepperd Pathfinder Award for his work in cancer research. In addition to his role at Generex, Dr. Terrell is a faculty member at the University of Texas at Austin Dell Medical School Department of Oncology where he serves as an industry and clinical expert for the Texas Health Catalyst Program supporting researchers, innovators, and entrepreneurs to accelerate the translation of ideas and innovations to health products.

The John Ben Shepperd Public Leadership Institute (https://shepperdinstitute.com) is named for John Ben Shepperd (1915-1990), who served as Texas Secretary of State (1950-1952) and Attorney General (1953-1957). John Ben Shepperd spent his life describing with great clarity the value of public service, mutual respect, ethics, and public leadership. The Pathfinder Award recognizes young Texas leaders who provide young Texans an education for and about leadership, ethics and public service. Awardees demonstrate leadership and high standards of ethics while serving as a volunteer, educator, philanthropist, and business leader.

“Congratulations to Dr. Terrell for being recognized by his community not only for his excellent scientific and clinical work in the fight against cancer, but also for his leadership and entrepreneurial skills that he has passed on to his students at UT Dell Medical School,” said Joe Moscato, President and Chief Executive Officer of Generex. “Dr. Terrell has been instrumental in our oncology clinical research efforts, and he continues to lead our M&A team as we build NuGenerex Immuno-Oncology into a world-class leader in the field of cancer immunotherapy. The Shepperd Pathfinder Award is well deserved, and we are thrilled to have Dr. Terrell on our Generex team.”

About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products. 

Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato
646-599-6222

Todd Falls
1-800-391-6755 Extension 222
investor@generex.com